Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04786158
Status:
COMPLETED
Last Update Posted:
2021-03-08
First Post:
2021-03-03
Brief Title:
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration APOPARKA
Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Organization:
Fondation Ophtalmologique Adolphe de Rothschild
Study Overview
Official Title:
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration APOPARKA
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APOPARKA
Brief Summary:
Treatment of tauopathies such as Progressive Supranuclear Palsy PSP and Cortico Basal Degeneration CBD remains a major challenge These rare severe neurodegenerative extrapyramidal movement disorders share phenotypic overlap and are usually painful Parkinson disease PD is a common extrapyramidal movement disorder and continuous subcutaneous apomorphine infusion CSAI is commonly used in advanced PD patients to alleviate motor and non-motor fluctuations Effects of subcutaneous apomorphine were investigated especially on pain and on quality of life in 7 patients with PSD or CBDThis is an observational real life surveillance-based studyThe Verbal Rating Scale for Pain VRS was used to assess changes in pain level and the clinical global impression-improvement scale CGI-I was used to assess changes in patients illness before and during six months of treatment Detailed report of the symptoms and side effects has been recorded by home nurses throughout the study period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None